Needham & Company maintains a 'Hold' on Acadia Pharmaceuticals (NASDAQ: ACAD).

Analyst, Alan Carr, said, "Results from the Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE